Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study

M. Fajfr, M. Balik, E. Cermakova, P. Bostik,

. 2020 ; 9 (8) : . [pub] 20200813

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20021814

Grantová podpora
Long term organization development plan Ministerstvo Obrany České Republiky
UHHK, 00179906 Ministerstvo Zdravotnictví Ceské Republiky

Fosfomycin represents a relatively old antibiotic, but it is experiencing a comeback in recent years. According to some studies, the increasing therapeutic use of this drug led to a rapid increase in the levels of resistance in bacteria causing urinary tract infection. In the presented study, levels of resistance to fosfomycin in more than 3500 bacterial isolates before and after fosfomycin introduction into therapeutic use in the Czech Republic and the clinical efficacy of treatment in 300 patients using this drug were assessed. The results show that the resistance levels to fosfomycin in Escherichia coli isolates before and after the drug registration were not significantly different (3.4% and 4.4%, respectively). In some other Gram-negative rods, such as otherwise susceptible Enterobacter, resistance to fosfomycin increased significantly from 45.6% to 76.6%. Fosfomycin treatment of urinary tract infections showed an excellent seven-day clinical efficacy (79.7%). However, when used to treat recurrent or complicated urinary tract infections, fosfomycin treatment was associated with high levels of infection relapse, leading to relapse in a total of 20.4% of patients during the first two months. This indicates that fosfomycin exhibits good efficacy only for the treatment of uncomplicated urinary tract infections.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021814
003      
CZ-PrNML
005      
20201204092807.0
007      
ta
008      
201125s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics9080511 $2 doi
035    __
$a (PubMed)32823650
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fajfr, Miroslav $u Institute of Clinical Microbiology, University Hospital, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Faculty of Medicine in Hradec Kralove, Charles University in Prague, Simkova 870, 500 38 Hradec Kralove, Czech Republic.
245    10
$a Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study / $c M. Fajfr, M. Balik, E. Cermakova, P. Bostik,
520    9_
$a Fosfomycin represents a relatively old antibiotic, but it is experiencing a comeback in recent years. According to some studies, the increasing therapeutic use of this drug led to a rapid increase in the levels of resistance in bacteria causing urinary tract infection. In the presented study, levels of resistance to fosfomycin in more than 3500 bacterial isolates before and after fosfomycin introduction into therapeutic use in the Czech Republic and the clinical efficacy of treatment in 300 patients using this drug were assessed. The results show that the resistance levels to fosfomycin in Escherichia coli isolates before and after the drug registration were not significantly different (3.4% and 4.4%, respectively). In some other Gram-negative rods, such as otherwise susceptible Enterobacter, resistance to fosfomycin increased significantly from 45.6% to 76.6%. Fosfomycin treatment of urinary tract infections showed an excellent seven-day clinical efficacy (79.7%). However, when used to treat recurrent or complicated urinary tract infections, fosfomycin treatment was associated with high levels of infection relapse, leading to relapse in a total of 20.4% of patients during the first two months. This indicates that fosfomycin exhibits good efficacy only for the treatment of uncomplicated urinary tract infections.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Balik, Michal $u Faculty of Medicine in Hradec Kralove, Charles University in Prague, Simkova 870, 500 38 Hradec Kralove, Czech Republic. Department of Urology, University Hospital, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Cermakova, Eva $u Faculty of Medicine in Hradec Kralove, Department of Medical Biophysics, Charles University in Prague, Simkova 870, 500 38 Hradec Kralove, Czech Republic.
700    1_
$a Bostik, Pavel $u Institute of Clinical Microbiology, University Hospital, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Faculty of Medicine in Hradec Kralove, Charles University in Prague, Simkova 870, 500 38 Hradec Kralove, Czech Republic. Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic.
773    0_
$w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 9, č. 8 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32823650 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201204092805 $b ABA008
999    __
$a ind $b bmc $g 1591523 $s 1112486
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 9 $c 8 $e 20200813 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
GRA    __
$a Long term organization development plan $p Ministerstvo Obrany České Republiky
GRA    __
$a UHHK, 00179906 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace